The pathology of multiple sclerosis

Claudia F. Lucchinetti, Joseph Parisi, Wolfgang Bruck

Research output: Contribution to journalArticlepeer-review

100 Scopus citations


The recognition of MS as a heterogeneous disorder with an inflammatory and a neurodegenerative phase requires the development of therapies that address not only the role of other targets in the disease (ie, myelin, oligodendrocyte, and axon) but also the role of different immune effector mechanisms (CD8 + T cells, antibody, complement, and so forth) and the potential need for different therapeutic strategies given at different stages of the disease. Recent genomic and proteomic technologic advances applied to MS neuropathology may help unravel the complexities of the MS lesion. Ultimately, the MS lesion is the target for therapy. A better understanding of the targets and mechanisms involved in lesion pathogenesis hopefully will lead to more effective therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)77-105
Number of pages29
JournalNeurologic clinics
Issue number1
StatePublished - Feb 2005

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'The pathology of multiple sclerosis'. Together they form a unique fingerprint.

Cite this